Up to $500



Official Title

Stride1 Study

Study Summary

To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD). This is a randomized, double-blind, active-controlled, 12-week, two-period study consisting of an open-label, bupropion lead-in period, and a double-blind treatment period. The trial is being conducted in subjects with treatment resistant MDD. Subjects will be considered to have treatment resistant MDD if they have had a historical inadequate response to 1 or 2 antidepressant treatments and a prospective inadequate response to treatment with bupropion during the open-label, lead-in period.

Eligibility and Recruitment Information

Recruitment Status Recruiting
Eligible Genders Both
Eligible Ages 18-65
Inclusion Diagnosed with treatment or treatment resistant depression.
Exclusion History of seizure disorder, anorexia nervosa, or bulimia; Currently hospitalized or residing in an in-patient facility during the study participation.
Start Date
Compensation Up to $500 USD
Location Orlando, FL

Study Information

Condition Depression
Study Phase Phase 2/3

Administrative Information

Study ID Mental Health
Investigators Sejal Patel, MD

Apply for this study

Please include your first name.
Please include your last name.
Please include a valid email address.
Thank you for applying.
Sorry, something wen't wrong. Please contact us for support.